Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001986044 | SCV002279760 | uncertain significance | Primary dilated cardiomyopathy | 2023-12-04 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 79 of the TXNRD2 protein (p.Arg79Trp). This variant is present in population databases (rs762060966, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with TXNRD2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1490788). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002443010 | SCV002733666 | uncertain significance | Cardiovascular phenotype | 2019-11-19 | criteria provided, single submitter | clinical testing | The p.R79W variant (also known as c.235C>T), located in coding exon 4 of the TXNRD2 gene, results from a C to T substitution at nucleotide position 235. The arginine at codon 79 is replaced by tryptophan, an amino acid with dissimilar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |